June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
August 2013 in “Nature Reviews Drug Discovery” New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.
The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.
December 2013 in “Cumhuriyet Tıp Dergisi/Cumhuriyet Üniversitesi Tıp Fakültesi dergisi” Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
5 citations
,
April 2011 in “Bioorganic & Medicinal Chemistry Letters” New Finasteride conjugate improves prostate treatment and vital signs in rats.
1 citations
,
April 2010 in “Cancer Research” WYE-130600 may cause skin thickening and irritation.
26 citations
,
January 2012 in “Journal of the American Academy of Dermatology” Eflornithine cream makes laser hair removal more effective for treating pseudofolliculitis barbae.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
April 2026 in “Journal of Cancer” Cepharanthine shows promise as a natural anticancer treatment.
1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
33 citations
,
June 2009 in “Journal of Cutaneous Pathology” Erlotinib can cause nonscarring hair loss and itchy skin.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
June 2018 in “The Journal of Sexual Medicine” Finasteride helps female-pattern hair loss.
6 citations
,
February 2023 in “Journal of nanobiotechnology” The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
July 2025 in “Journal of Investigative Dermatology” November 2008 in “Cancer Prevention Research” Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
June 2021 in “Research Square (Research Square)” Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
3 citations
,
January 2025 in “International Journal of Biological Macromolecules” A new microneedle patch effectively promotes hair regrowth with less frequent dosing.